Maintenance rituximab every 2 months is more toxic than every 3 months in patients with non-Hodgkin lymphoma

Blood

Volumn 125, Issue 21, 2015, Pages 3354-3355

  Rashidi, Armin ^a   Oak, Eunhye ^a   Bartlett, Nancy L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; CANCER SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG WITHDRAWAL; FEMALE; HEALTH CARE QUALITY; HUMAN; INFECTION; LETTER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT DURATION; WALDENSTROEM MACROGLOBULINEMIA; AGED; LYMPHOMA, NON-HODGKIN; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RITUXIMAB;

EID: 84983434347     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-02-628362     Document Type: Letter

References (2)

1. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377(9759):42-51.
2. Salles GA, Seymour JF, Feugier P, et al. Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy [abstract]. Blood. 2013; 122(21). Abstract 509.